Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Topical 5-fluorouracil, interferon alfa-2b eye drops both effective, safe for OSSN

15 Dec 2018

Topical 5-fluorouracil 1% (5FU) is as good as interferon alfa-2b 1 MIU/mL (IFN) eye drops in the primary treatment of ocular surface squamous neoplasia (OSSN), with both modalities leading to high tumour resolution and low recurrence rates, a recent study has shown.

Researchers examined the medical records of 54 patients who received 5FU and 48 patients who received IFN as primary therapy for OSSN. Primary outcome measures included the frequency of clinical resolution and time to OSSN recurrence. Secondary outcome was the frequency of side effects with each therapy.

The mean age of the cohort was 68 years, and a greater proportion of Hispanics were treated with 5FU. In a univariable analysis, the frequency of OSSN resolution was higher with 5FU than with IFN (96.3 percent vs 81.3 percent; p=0.01). However, multivariable analysis showed that treatment modality was not a significant predictor of resolution.

Among patients with resolved OSSN, mean time to resolution was similar between 5FU and IFN (mean 6.6 vs 5.5 months; p=0.17). Likewise, there was no significant difference in the number of resolved lesions that recurred (6 of 52 eyes vs 2 of 39 eyes, respectively; p=0.46), with Kaplan Meier survival curves of OSSN recurrence being similar between the two teatment groups (log rank=0.16).

Recurrence rates at 1 year were 11.4 percent with 5FU and 4.5 percent with IFN. Adverse events such as eyelid oedema (p=0.04) and tearing (p=0.02) were more significant with 5FU.

The present data suggest that both topical 5FU and IFN eye drops are effective treatment options for OSSN.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.